Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed, the hematological benefit during eculizumab t...

Full description

Bibliographic Details
Published in:	Frontiers in Immunology
Main Authors:	Antonio M. Risitano, Serena Marotta, Patrizia Ricci, Luana Marano, Camilla Frieri, Fabiana Cacace, Michela Sica, Austin Kulasekararaj, Rodrigo T. Calado, Phillip Scheinberg, Rosario Notaro, Regis Peffault de Latour
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-06-01
Subjects:	paroxysmal nocturnal hemoglobinuria intravascular hemolysis extravascular hemolysis complement inhibition eculizumab ravulizumab
Online Access:	https://www.frontiersin.org/article/10.3389/fimmu.2019.01157/full

Similar Items

Hematological response in patients with paroxysmal nocturnal hemoglobinuria treated with C5-inhibitor
by: V. D. Latyshev, et al.
Published: (2024-01-01)

Consensus on Complement Inhibitor Therapy and Management of Paroxysmal Nocturnal Hemoglobinuria
by: Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association
Published: (2025-01-01)

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies
by: Elisavet Apostolidou, et al.
Published: (2025-09-01)

Presentation and management of paroxysmal nocturnal hemoglobinuria: a single-center experience
by: Mehmet Sinan Dal, et al.
Published: (2016-03-01)

Efficacy and safety of current treatments for paroxysmal nocturnal hemoglobinuria: A systematic review
by: Yara Maria da Silva Pires, et al.
Published: (2023-12-01)

Eculizumab Treatment of Massive Hemolysis Occurring in a Rare Co-Existence of Paroxysmal Nocturnal Hemoglobinuria and Myasthenia Gravis
by: Ráhel Réka Bicskó, et al.
Published: (2024-04-01)

Eculizumab treatment for Chinese patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH): efficacy and safety – a single-center study
by: Leyu Wang, et al.
Published: (2025-12-01)

Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes
by: Michela Sica, et al.
Published: (2017-06-01)

Case Report: Iptacopan in a paroxysmal nocturnal hemoglobinuria patient with severe renal insufficiency
by: Ting Wu, et al.
Published: (2025-08-01)

Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH
by: Weitz IC
Published: (2023-03-01)

Paroxysmal nocturnal hemoglobinuria: Pandora’s box?
by: Mihnea-Alexandru Găman, et al.
Published: (2020-10-01)

Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary
by: Celso Arrais, et al.
Published: (2025-07-01)

Renal hemosiderosis in paroxysmal nocturnal hemoglobinuria
by: Italo Gustavo Lima Monteiro, et al.
Published: (2022-07-01)

Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature
by: Nicole Galli, et al.
Published: (2023-10-01)

National clinical guidelines for the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria
by: A. D. Kulagin, et al.
Published: (2014-09-01)

National clinical guidelines for the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria
by: A. D. Kulagin, et al.
Published: (2014-09-01)

Classic paroxysmal nocturnal hemoglobinuria: A puzzling case of hemolytic anemia without cytopenia
by: Majed Abdul Basit Momin, et al.
Published: (2025-01-01)

Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
by: Vasantha Mallenahalli Neeekantappa, et al.
Published: (2024-02-01)

Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network
by: Jesse Fishman, et al.
Published: (2023-04-01)

A case of paroxysmal nocturnal hemoglobinuria with renal hemosiderosis
by: Parimal B Patel, et al.
Published: (2019-01-01)

Detection of somatic mutations of the PIG-A gene in Brazilian patients with paroxysmal nocturnal hemoglobinuria
by: R. Franco de Carvalho, et al.
Published: (2001-06-01)

The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis
by: Armando Martinez Salazar, et al.
Published: (2025-05-01)

Role of complement in myasthenia gravis
by: Pyae Phyo San, et al.
Published: (2023-10-01)

A hyper-acute immune hemolytic anemia induced by contrast medium was successfully treated with eculizumab: a case report
by: Sabine Hermann, et al.
Published: (2025-02-01)

Recurrent Acute Renal Failure in a Patient with Aplastic Anemia‐Paroxysmal Nocturnal Hemoglobinuria Syndrome: A Case Report
by: Szu‐Chia Chen, et al.
Published: (2007-11-01)

Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
by: Di Matteo S, et al.
Published: (2024-04-01)

Cerebral stroke in a teenage girl with paroxysmal nocturnal hemoglobinuria
by: Francesco Gervasi, et al.
Published: (2017-06-01)

Eculizumab for paroxysmal nocturnal hemoglobinuria: Two cases of successful pregnancy outcomes
by: Jovanka Ilic, et al.
Published: (2024-05-01)

Effect of Dietary Phosphate Deprivation on Red Blood Cell Parameters of Periparturient Dairy Cows
by: Lianne M. van den Brink, et al.
Published: (2023-01-01)

Treatment of paroxysmal nocturnal hemoglobinuria
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Treatment of paroxysmal nocturnal hemoglobinuria
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Spontaneous Remission in Paroxysmal Nocturnal Hemoglobinuria: An Extremely Rare Case
by: Özgür Mehtap, et al.
Published: (2022-05-01)

Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety
by: Sangam Shah, et al.
Published: (2022-07-01)

COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study
by: Leyu Wang, et al.
Published: (2023-12-01)

Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies
by: Alfredo Damasceno, et al.
Published: (2025-02-01)

Targeted management of coexistent severe thrombophilias—A case report of a successful pregnancy despite paroxysmal nocturnal hemoglobinuria and hereditary protein C deficiency
by: Julien Dereme, et al.
Published: (2024-10-01)

Successful switch from pegcetacoplan to iptacopan after repeated severe breakthrough hemolysis events – case report
by: Wolfgang Füreder, et al.
Published: (2025-12-01)

Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuria
by: Hakan Göker, et al.
Published: (2011-08-01)

Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuria
by: Hakan Göker, et al.
Published: (2011-09-01)

Long standing eculizumab treatment without anticoagulant therapy in high-risk thrombogenic paroxysmal nocturnal hemoglobinuria
by: Hassan A. Al-Jafar, et al.
Published: (2015-09-01)